Evaluating Biomarkers During Clinical Trials for Immunotherapies: A Case Study on the Pioneer Project
In this free webinar, Dr Jérôme Galon, Research Director at Inserm, will explain how biomarker evaluation allows a comprehensive profiling of the tumor and is mandatory to elucidate actionable or resistance mechanisms to treatment in solid cancers.
Webinar Type: Recorded
Jérôme Galon, PhD, Director, Inserm UMRS1138, Cordeliers Research Center, Paris, France
Jérôme Galon is the director at INSERM (French NIH) and head of the laboratory of Integrative Cancer Immunology, in Paris, France. He is also associate director and co-founder of the European Academy of Tumor Immunology (EATI), board member of the Society for Immunotherapy of Cancer (SITC), co-founder of HalioDx company and the chairman of its scientific council. His work on the comprehensive analysis of the tumor microenvironment led to the concept of cancer immune contexture. He pioneered Immunoscore and is the principal investigator of the Worldwide Immunoscore Consortium. His contributions have been recognized with numerous awards, including the William B. Coley Award, USA.
Fabrice Barlesi, MD, PhD, Head of Multidisciplinary Oncology and Therapeutic Innovations, APHM, Coordinator of the Center of Early Phase Cancer Trials of Marseille CLIP2, Professor of Medicine, Aix-Marseille University
Professor Fabrice Barlesi is the head of the multidisciplinary oncology and therapeutic innovations department at Aix Marseille University and coordinator of the Early-Phase Cancer Trials Center (Phase I unit). He is an expert in innovative clinical approaches to pulmonary cancers. He is also responsible for organizing master courses in Lung Cancer Molecular Biology in Marseille Medical University (AMU/AP-HM) and the PIONeeR project, which constitutes a clear illustration of progresses and perspectives in the field.